Schlatter J, Nguyen D, Zamy M, Kabiche S, Fontan J, Cisternino S
Eur Spine J. 2017; 28(1):21-30.
PMID: 29151132
DOI: 10.1007/s00586-017-5387-x.
Valgus J, Singer E, Berry S, Rathmell W
J Oncol Pract. 2013; 9(2):e21-3.
PMID: 23814521
PMC: 3595447.
DOI: 10.1200/JOP.2012.000779.
Tappeiner C, Garweg J
Graefes Arch Clin Exp Ophthalmol. 2011; 249(12):1831-5.
PMID: 21850439
DOI: 10.1007/s00417-011-1783-9.
Lee H, Im S, Kang M, Kim K, Kim S, Kim H
Yonsei Med J. 2008; 49(1):151-4.
PMID: 18306482
PMC: 2615263.
DOI: 10.3349/ymj.2008.49.1.151.
Berg S, Chamberlain M
Curr Oncol Rep. 2002; 5(1):29-40.
PMID: 12493148
DOI: 10.1007/s11912-003-0084-9.
Adverse drug events related to dosage forms and delivery systems.
Uchegbu I, Florence A
Drug Saf. 1996; 14(1):39-67.
PMID: 8713487
DOI: 10.2165/00002018-199614010-00005.
Side effects of intrathecal and epidural opioids.
Chaney M
Can J Anaesth. 1995; 42(10):891-903.
PMID: 8706199
DOI: 10.1007/BF03011037.
Cerebral arterial disturbances in a transient encephalopathy induced by methotrexate.
Follezou J, Chauveinc L, Guerin J
Med Oncol Tumor Pharmacother. 1993; 10(4):181-3.
PMID: 8164455
DOI: 10.1007/BF02989667.
CT studies before and after CNS treatment for acute lymphoblastic leukemia and malignant non-hodgkin's lymphoma in childhood.
Kretzschmar K, Gutjahr P, Kutzner J
Neuroradiology. 1980; 20(4):173-80.
PMID: 6970344
DOI: 10.1007/BF00336678.
Calcified cerebral necrosis following ALL therapy.
Muller K, Menne R, BACHMANN K, Grobe H
J Cancer Res Clin Oncol. 1981; 102(1):81-91.
PMID: 6949906
DOI: 10.1007/BF00410537.
Necrotizing myelopathy associated with acute lymphoblastic leukemia. Case report and review of literature.
Grisold W, Lutz D, Wolf D
Acta Neuropathol. 1980; 49(3):231-5.
PMID: 6929156
DOI: 10.1007/BF00707111.
Vascular changes of methotrexate-related disseminated necrotizing leukoencephalopathy.
Suzuki K, Takemura T, Okeda R, Hatakeyama S
Acta Neuropathol. 1984; 65(2):145-9.
PMID: 6596829
DOI: 10.1007/BF00690468.
Letter: Neurotoxicity of intrathecal chemotherapy for leukaemia.
Marmont A, Damasio E
Br Med J. 1973; 4(5883):47.
PMID: 4518764
PMC: 1587099.
DOI: 10.1136/bmj.4.5883.47-a.
Acute neurological toxicity of intrathecal cytosine arabinoside. A case report.
Crawford S, Rustin G, Bagshawe K
Cancer Chemother Pharmacol. 1986; 16(3):306-7.
PMID: 3698171
DOI: 10.1007/BF00293998.
Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA for meningeal involvement by malignancies.
Stewart D, Maroun J, Hugenholtz H, Benoit B, Girard A, Richard M
J Neurooncol. 1987; 5(4):315-22.
PMID: 3126273
DOI: 10.1007/BF00148388.
Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).
Golightly L, Smolinske S, Bennett M, Sutherland 3rd E, Rumack B
Med Toxicol Adverse Drug Exp. 1988; 3(3):209-40.
PMID: 3041246
DOI: 10.1007/BF03259883.
Acute reversible neurological deficit following intrathecal chemotherapy.
Dunkelman H, Earl H, Twelves C
Cancer Chemother Pharmacol. 1991; 27(4):329-30.
PMID: 1998991
DOI: 10.1007/BF00685121.
Intrathecal 5-fluorouracil in the rhesus monkey.
Berg S, Balis F, McCully C, Parker G, Murphy R, Poplack D
Cancer Chemother Pharmacol. 1992; 31(2):127-30.
PMID: 1451233
DOI: 10.1007/BF00685099.
Acute ascending poliomyelomalacia after treatment of acute lymphocytic leukemia.
REZNIK M
Acta Neuropathol. 1979; 45(2):153-7.
PMID: 283679
DOI: 10.1007/BF00691894.
